Huayi passed remote GMP re-inspection by MHRA

On 23rd June, 2021, Huayi passed remote GMP re-inspection by MHRA including new workshops for moderately potency product and oral liquid.

Since the first MHRA inspection in 2010, Huayi has passed three EU GMP re-inspections totally. Huayi has successfully commercialized over 50 products and delivered more than 10 billion tablets/capsules to EU and UK up to now.

With new moderately potency workshop and oral liquid workshop get approved, Huayi extends the capability of manufacturing and supplying new dosage form. The moderately potency workshop has annual capability of 300 million tablets, and the oral liquid workshop is capable of manufacturing 6 million bottles annually.